Trade Amgen - AMGN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.99 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.030779% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.013666% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Amgen Inc ESG Risk Ratings
‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly
Prev. Close* | 254.36 |
Open* | 253.53 |
1-Year Change* | 14.27% |
Day's Range* | 252.47 - 254.62 |
52 wk Range | 214.39-296.67 |
Average Volume (10 days) | 2.06M |
Average Volume (3 months) | 54.34M |
Market Cap | 136.00B |
P/E Ratio | 20.42 |
Shares Outstanding | 533.58M |
Revenue | 26.33B |
EPS | 12.48 |
Dividend (Yield %) | 3.34275 |
Beta | 0.65 |
Next Earnings Date | Feb 1, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jan 27, 2023 | 253.18 | -1.00 | -0.39% | 254.18 | 254.78 | 252.16 |
Jan 26, 2023 | 254.36 | -0.58 | -0.23% | 254.94 | 256.12 | 252.57 |
Jan 25, 2023 | 256.02 | -3.70 | -1.42% | 259.72 | 261.13 | 255.52 |
Jan 24, 2023 | 259.11 | -0.41 | -0.16% | 259.52 | 261.45 | 256.93 |
Jan 23, 2023 | 260.45 | -2.68 | -1.02% | 263.13 | 264.27 | 259.31 |
Jan 20, 2023 | 262.82 | 3.73 | 1.44% | 259.09 | 263.44 | 258.02 |
Jan 19, 2023 | 261.49 | 0.26 | 0.10% | 261.23 | 263.11 | 260.31 |
Jan 18, 2023 | 263.82 | -5.06 | -1.88% | 268.88 | 269.60 | 262.76 |
Jan 17, 2023 | 268.83 | -1.89 | -0.70% | 270.72 | 273.40 | 268.32 |
Jan 13, 2023 | 271.36 | 2.20 | 0.82% | 269.16 | 271.74 | 269.16 |
Jan 12, 2023 | 270.44 | 0.00 | 0.00% | 270.44 | 271.57 | 268.00 |
Jan 11, 2023 | 272.26 | -2.85 | -1.04% | 275.11 | 275.97 | 269.55 |
Jan 10, 2023 | 273.41 | 4.07 | 1.51% | 269.34 | 274.15 | 268.61 |
Jan 9, 2023 | 269.67 | -3.70 | -1.35% | 273.37 | 274.39 | 268.16 |
Jan 6, 2023 | 274.64 | 7.41 | 2.77% | 267.23 | 276.36 | 267.23 |
Jan 5, 2023 | 266.37 | 3.77 | 1.44% | 262.60 | 267.59 | 261.16 |
Jan 4, 2023 | 264.03 | 1.92 | 0.73% | 262.11 | 264.60 | 260.54 |
Jan 3, 2023 | 261.04 | 3.44 | 1.34% | 257.60 | 262.13 | 256.83 |
Dec 30, 2022 | 262.13 | 1.20 | 0.46% | 260.93 | 262.67 | 258.89 |
Dec 29, 2022 | 262.64 | -0.14 | -0.05% | 262.78 | 264.46 | 259.79 |
Amgen Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total revenue | 22991 | 22849 | 23747 | 23362 | 25424 | 25979 |
Revenue | 22991 | 22849 | 23747 | 23362 | 25424 | 25979 |
Cost of Revenue, Total | 4162 | 4069 | 4101 | 4356 | 6159 | 6454 |
Gross Profit | 18829 | 18780 | 19646 | 19006 | 19265 | 19525 |
Total Operating Expense | 13197 | 12876 | 13404 | 13688 | 16285 | 18340 |
Selling/General/Admin. Expenses, Total | 5062 | 4870 | 5332 | 5150 | 5730 | 6873 |
Research & Development | 3840 | 3562 | 3737 | 4116 | 4207 | 4819 |
Unusual Expense (Income) | -6 | 367 | 292 | 47 | ||
Other Operating Expenses, Total | 139 | 8 | -58 | 19 | 189 | 194 |
Operating Income | 9794 | 9973 | 10343 | 9674 | 9139 | 7639 |
Interest Income (Expense), Net Non-Operating | -631 | -376 | -798 | -536 | -1006 | -1197 |
Net Income Before Taxes | 9163 | 9597 | 9545 | 9138 | 8133 | 6701 |
Net Income After Taxes | 7722 | 8079 | 8394 | 7842 | 7264 | 5893 |
Net Income Before Extra. Items | 7722 | 8079 | 8394 | 7842 | 7264 | 5893 |
Net Income | 7722 | 1979 | 8394 | 7842 | 7264 | 5893 |
Income Available to Common Excl. Extra. Items | 7722 | 8079 | 8394 | 7842 | 7264 | 5893 |
Income Available to Common Incl. Extra. Items | 7722 | 1979 | 8394 | 7842 | 7264 | 5893 |
Diluted Net Income | 7722 | 1979 | 8394 | 7842 | 7264 | 5893 |
Diluted Weighted Average Shares | 754 | 735 | 665 | 609 | 590 | 573 |
Diluted EPS Excluding Extraordinary Items | 10.2414 | 10.9918 | 12.6226 | 12.8769 | 12.3119 | 10.2845 |
Dividends per Share - Common Stock Primary Issue | 4 | 4.6 | 5.28 | 5.8 | 6.4 | 7.04 |
Diluted Normalized EPS | 10.2347 | 11.4122 | 13.0087 | 12.9431 | 12.3119 | 10.2845 |
Total Extraordinary Items | -6100 | |||||
Other, Net | 259 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total revenue | 5901 | 6526 | 6706 | 6846 | 6238 |
Revenue | 5901 | 6526 | 6706 | 6846 | 6238 |
Cost of Revenue, Total | 1490 | 1637 | 1609 | 1718 | 1561 |
Gross Profit | 4411 | 4889 | 5097 | 5128 | 4677 |
Total Operating Expense | 3772 | 5698 | 4328 | 4542 | 3738 |
Selling/General/Admin. Expenses, Total | 1254 | 2889 | 1305 | 1425 | 1228 |
Research & Development | 967 | 1082 | 1422 | 1348 | 959 |
Other Operating Expenses, Total | 61 | 90 | -8 | 51 | -10 |
Operating Income | 2129 | 828 | 2378 | 2304 | 2500 |
Interest Income (Expense), Net Non-Operating | -285 | -281 | -296 | -335 | -295 |
Other, Net | 13 | 11 | 73 | 162 | -530 |
Net Income Before Taxes | 1857 | 558 | 2155 | 2131 | 1675 |
Net Income After Taxes | 1646 | 464 | 1884 | 1899 | 1476 |
Net Income Before Extra. Items | 1646 | 464 | 1884 | 1899 | 1476 |
Net Income | 1646 | 464 | 1884 | 1899 | 1476 |
Income Available to Common Excl. Extra. Items | 1646 | 464 | 1884 | 1899 | 1476 |
Income Available to Common Incl. Extra. Items | 1646 | 464 | 1884 | 1899 | 1476 |
Diluted Net Income | 1646 | 464 | 1884 | 1899 | 1476 |
Diluted Weighted Average Shares | 581 | 576 | 570 | 564 | 551 |
Diluted EPS Excluding Extraordinary Items | 2.83305 | 0.80556 | 3.30526 | 3.36702 | 2.67877 |
Dividends per Share - Common Stock Primary Issue | 1.76 | 1.76 | 1.76 | 1.76 | 1.94 |
Diluted Normalized EPS | 2.83305 | 0.80556 | 3.30526 | 3.36702 | 2.67877 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Current Assets | 46010 | 49476 | 37618 | 18440 | 21144 | 19385 |
Cash and Short Term Investments | 38085 | 41678 | 29304 | 8911 | 10647 | 8037 |
Cash & Equivalents | 3241 | 3800 | 6945 | 6037 | 6266 | 7989 |
Short Term Investments | 34844 | 37878 | 22359 | 2874 | 4381 | 48 |
Total Receivables, Net | 3165 | 3237 | 3580 | 4057 | 5324 | 5839 |
Accounts Receivable - Trade, Net | 3165 | 3237 | 3580 | 4057 | 4525 | 4895 |
Total Inventory | 2745 | 2834 | 2940 | 3584 | 3893 | 4086 |
Other Current Assets, Total | 2015 | 1727 | 1794 | 1888 | 124 | 200 |
Total Assets | 77626 | 79954 | 66416 | 59707 | 62948 | 61165 |
Property/Plant/Equipment, Total - Net | 4961 | 4989 | 4958 | 5397 | 5297 | 5750 |
Property/Plant/Equipment, Total - Gross | 12427 | 12579 | 12754 | 13754 | 14274 | 14548 |
Accumulated Depreciation, Total | -7466 | -7590 | -7796 | -8357 | -8977 | -8798 |
Goodwill, Net | 14751 | 14761 | 14699 | 14703 | 14689 | 14890 |
Intangibles, Net | 10279 | 8609 | 7443 | 19413 | 16587 | 15182 |
Long Term Investments | 501 | 570 | 1176 | 573 | ||
Other Long Term Assets, Total | 1124 | 1549 | 1698 | 1754 | 4055 | 5385 |
Total Current Liabilities | 11204 | 9020 | 13488 | 12835 | 11653 | 12184 |
Accounts Payable | 917 | 1352 | 1207 | 1371 | 1421 | 1366 |
Accrued Expenses | 4964 | 5563 | 6948 | 7565 | 8295 | 8947 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 4403 | 1152 | 4419 | 2953 | 91 | 87 |
Other Current Liabilities, Total | 920 | 953 | 914 | 946 | 1846 | 1784 |
Total Liabilities | 47751 | 54713 | 53916 | 50034 | 53539 | 54465 |
Total Long Term Debt | 30193 | 34190 | 29510 | 26950 | 32895 | 33222 |
Long Term Debt | 30193 | 34190 | 29510 | 26950 | 32895 | 33222 |
Deferred Income Tax | 2436 | 1166 | 864 | 606 | ||
Other Liabilities, Total | 3918 | 10337 | 10054 | 9643 | 8991 | 9059 |
Total Equity | 29875 | 25241 | 12500 | 9673 | 9409 | 6700 |
Common Stock | 30784 | 30992 | 31246 | 31531 | 31802 | 32096 |
Retained Earnings (Accumulated Deficit) | -438 | -5072 | -17977 | -21330 | -21408 | -24600 |
Unrealized Gain (Loss) | -138 | -144 | -338 | 22 | 1 | |
Other Equity, Total | -333 | -535 | -431 | -550 | -986 | -796 |
Total Liabilities & Shareholders’ Equity | 77626 | 79954 | 66416 | 59707 | 62948 | 61165 |
Total Common Shares Outstanding | 738.2 | 722.2 | 629.6 | 591.4 | 578.3 | 558.3 |
Prepaid Expenses | 1156 | 1223 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 21299 | 19099 | 24380 | 19385 | 18520 |
Cash and Short Term Investments | 10566 | 8082 | 12921 | 8037 | 6544 |
Cash & Equivalents | 6112 | 6630 | 11969 | 7989 | 6528 |
Short Term Investments | 4454 | 1452 | 952 | 48 | 16 |
Total Receivables, Net | 4423 | 4479 | 4765 | 4895 | 5077 |
Accounts Receivable - Trade, Net | 4423 | 4479 | 4765 | 4895 | 5077 |
Total Inventory | 4017 | 4115 | 4152 | 4086 | 4411 |
Other Current Assets, Total | 2293 | 2423 | 2542 | 2367 | 2488 |
Total Assets | 62539 | 59773 | 64993 | 61165 | 59196 |
Property/Plant/Equipment, Total - Net | 4855 | 4906 | 4982 | 5184 | 5142 |
Goodwill, Net | 14673 | 14676 | 14665 | 14890 | 14897 |
Intangibles, Net | 15947 | 15308 | 14659 | 15182 | 14567 |
Other Long Term Assets, Total | 5765 | 5784 | 6307 | 6524 | 6070 |
Total Current Liabilities | 12869 | 14585 | 14842 | 12184 | 12886 |
Accounts Payable | 1396 | 1277 | 1171 | 1366 | 1403 |
Accrued Expenses | 9917 | 8984 | 9383 | 10731 | 10639 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1556 | 4324 | 4288 | 87 | 844 |
Total Liabilities | 53205 | 51526 | 56776 | 54465 | 58280 |
Total Long Term Debt | 31129 | 28458 | 33291 | 33222 | 36010 |
Long Term Debt | 31129 | 28458 | 33291 | 33222 | 36010 |
Other Liabilities, Total | 9207 | 8483 | 8643 | 9059 | 9384 |
Total Equity | 9334 | 8247 | 8217 | 6700 | 916 |
Common Stock | 31806 | 31877 | 31989 | 32096 | 31247 |
Retained Earnings (Accumulated Deficit) | -21639 | -22762 | -22964 | -24600 | -29568 |
Unrealized Gain (Loss) | 1 | 1 | 0 | 0 | |
Other Equity, Total | -834 | -869 | -808 | -796 | -763 |
Total Liabilities & Shareholders’ Equity | 62539 | 59773 | 64993 | 61165 | 59196 |
Total Common Shares Outstanding | 575.3 | 569.6 | 565 | 558.3 | 534.2 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Net income/Starting Line | 7722 | 1979 | 8394 | 7842 | 7264 | 5893 |
Cash From Operating Activities | 10354 | 11177 | 11296 | 9150 | 10497 | 9261 |
Cash From Operating Activities | 2105 | 1955 | 1946 | 2206 | 3601 | 3398 |
Deferred Taxes | 183 | -1330 | -363 | -289 | -287 | -453 |
Non-Cash Items | 343 | 663 | 697 | 122 | 135 | 1617 |
Cash Taxes Paid | 1100 | 1500 | 1900 | 1900 | 1400 | 1900 |
Cash Interest Paid | 1300 | 1300 | 1500 | 1300 | 1200 | 1200 |
Changes in Working Capital | 1 | 7910 | 622 | -731 | -216 | -1194 |
Cash From Investing Activities | -8658 | -4024 | 14339 | 5709 | -5401 | 733 |
Capital Expenditures | -837 | -664 | -738 | -618 | -608 | -880 |
Other Investing Cash Flow Items, Total | -7821 | -3360 | 15077 | 6327 | -4793 | 1613 |
Cash From Financing Activities | -2599 | -6594 | -22490 | -15767 | -4867 | -8271 |
Financing Cash Flow Items | -284 | -140 | -68 | -42 | -90 | -78 |
Total Cash Dividends Paid | -2998 | -3365 | -3507 | -3509 | -3755 | -4013 |
Issuance (Retirement) of Stock, Net | -2910 | -3160 | -17794 | -7702 | -3486 | -4975 |
Issuance (Retirement) of Debt, Net | 3593 | 71 | -1121 | -4514 | 2464 | 795 |
Net Change in Cash | -903 | 559 | 3145 | -908 | 229 | 1723 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 1646 | 2110 | 3994 | 5893 | 1476 |
Cash From Operating Activities | 2104 | 4035 | 6453 | 9261 | 2164 |
Cash From Operating Activities | 841 | 1696 | 2546 | 3398 | 841 |
Deferred Taxes | -91 | -137 | -264 | -453 | -251 |
Non-Cash Items | 79 | 1675 | 1692 | 1617 | 545 |
Changes in Working Capital | -371 | -1309 | -1515 | -1194 | -447 |
Cash From Investing Activities | -319 | 890 | 963 | 733 | -111 |
Capital Expenditures | -166 | -351 | -593 | -880 | -190 |
Other Investing Cash Flow Items, Total | -153 | 1241 | 1556 | 1613 | 79 |
Cash From Financing Activities | -1939 | -4561 | -1713 | -8271 | -3514 |
Financing Cash Flow Items | -52 | -85 | -104 | -78 | -26 |
Total Cash Dividends Paid | -1016 | -2024 | -3023 | -4013 | -1080 |
Issuance (Retirement) of Stock, Net | -871 | -2452 | -3532 | -4975 | -6360 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 4946 | 795 | 3952 |
Net Change in Cash | -154 | 364 | 5703 | 1723 | -1461 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.849 | 47216165 | 1317764 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.4633 | 29151093 | 277320 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.4487 | 29073061 | -207866 | 2022-09-30 | LOW |
PRIMECAP Management Company | Investment Advisor | 2.9171 | 15564870 | -73750 | 2022-09-30 | LOW |
Capital Research Global Investors | Investment Advisor | 2.3624 | 12605265 | -1490071 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 2.0992 | 11200793 | 502787 | 2022-09-30 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 1.7311 | 9236530 | 287899 | 2022-09-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 1.5266 | 8145601 | -212030 | 2022-09-30 | LOW |
Morgan Stanley Smith Barney LLC | Investment Advisor | 1.5255 | 8139945 | -45470 | 2022-09-30 | LOW |
Invesco Capital Management (QQQ Trust) | Investment Advisor | 1.334 | 7118039 | -705787 | 2022-12-31 | LOW |
Wells Fargo Advisors | Research Firm | 1.3251 | 7070379 | 59546 | 2022-09-30 | LOW |
Goldman Sachs & Company, Inc. | Research Firm | 1.2368 | 6599371 | 1971000 | 2022-09-30 | MED |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.9488 | 5062588 | -492241 | 2021-12-31 | LOW |
BlackRock Asset Management Ireland Limited | Investment Advisor | 0.9193 | 4905395 | 163471 | 2022-09-30 | LOW |
Aristotle Capital Management, LLC | Investment Advisor | 0.9165 | 4890166 | -72128 | 2022-09-30 | LOW |
BofA Global Research (US) | Research Firm | 0.8962 | 4781857 | -445255 | 2022-09-30 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.8092 | 4317814 | -103045 | 2022-09-30 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.7975 | 4255525 | -170586 | 2022-09-30 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.7689 | 4102655 | -193979 | 2022-09-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 0.7674 | 4094846 | 20049 | 2022-09-30 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com GroupTraders
Active clients monthly
Monthly investing volume
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Amgen Company profile
About Amgen, Inc.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Amgen, Inc. revenues increased 2% to $25.98B. Net income decreased 19% to $5.89B. Revenues reflect Other revenues segment increase of 42% to $1.68B, Prolia segment increase of 18% to $3.25B, ROW segment increase of 12% to $7.01B, Other revenues segment increase of 42% to $1.68B. Net income was offset by Research and development increase of 15% to $4.82B (expense), Other increase of 3% to $194M (expense).
Equity composition
Common Stock $.0001 Par, 4/11, 2.75B auth., 929,730,507 issd. Insiders own 0.12% . IPO 5/87, 2M shares @ $34 by Paine Webber. 9/91, 3-for-1 split; 11/99, 3/99, 8/95, 7/90, 2-for-1 splits. 7/02, Company acquired Immunex Corp. @ $4.50/share and 0.44 shs. (242,916,735 shs. issd.).
Industry: | Pharmaceuticals (NEC) |
One Amgen Center Drive
THOUSAND OAKS
CALIFORNIA 91320-1799
US
Income Statement
- Annual
- Quarterly
News

FX Weekly Outlook: USD, GBP/USD, EUR/USD Analysis
USD, GBP/USD, EUR/USD forecasts for the week ahead.
16:33, 27 January 2023
WTI, Gold, Silver – commodities weekly forecast for the week ahead
Strength to strength in the commodity space, however, topside exhaustion begins to creep in
13:53, 27 January 2023
S&P 500, Nasdaq, DAX 40, Hang Seng technical update
Can the S&P 500 hold above its 2022 descending trend line?
12:44, 26 January 2023
Amazon Q4 earnings: online retailer to feel the pinch of higher costs and slowing consumer spending
AMZN Q4 earnings preview and technical analysis
09:59, 25 January 2023
Canadian Dollar Forecast: Bank of Canada Heading Towards a Final Rate Hike
Bank of Canada expected to hike 25bps at its upcoming meeting. Focus on whether the BoC announces a pause going forward.
15:49, 24 January 2023People also watch
Still looking for a broker you can trust?
Join the 480.000+ traders worldwide that chose to trade with Capital.com